



**January 22**

**Wednesday**

**12:00 – 1:00 PM EST/EDT**

[learn.unclcn.org/01222025](https://learn.unclcn.org/01222025)



Available in one month

[learn.unclcn.org/spoc](https://learn.unclcn.org/spoc)

## UNCLCN SITES

UNCLCN Website [unclcn.org](https://unclcn.org)

Learning Portal [learn.unclcn.org](https://learn.unclcn.org)

Live Webinars [learn.unclcn.org/live](https://learn.unclcn.org/live)



## Antibody-Drug Conjugates in Oncology: From Bench to Bedside



**Kevin Chen**, PharmD, MS, BCOB, CPP

*Clinical Pharmacist Practitioner*

Practice Advancement and Clinical Education

UNC Lineberger Comprehensive Cancer Center

UNC School of Medicine

University of North Carolina at Chapel Hill

### Webinar Description

Antibody drug conjugates have seen a rise in use for the treatment of many different types of cancer. These agents possess a unique mechanism of action different than our prior cancer-directed therapies. Kevin Chen, PharmD, MS, BCOB, CPP, will dive deeper into their structure and pharmacology, key landmark trials highlighting their benefit, and current toxicity challenges limiting their potential, with the goal for attendees to better understand these novel therapeutic agents and incorporate them into their practice.

### Learning Objectives

- Describe the components of an antibody drug conjugate and its mechanism of action
- Discuss clinical evidence supporting their use as cancer treatment
- Identify strategies to improve efficacy and tolerability of these novel agents

### DISCLOSURE STATEMENTS

**Activity Directors:** This activity has been planned and implemented under the sole supervision of the Course Director, Stephanie Wheeler, PhD, MPH, and Emily Ray, MD, of the UNC School of Medicine in association with the UNC Office of Continuing Professional Development (CPD). Dr. Wheeler received research support from AstraZeneca (ended June 2023) and Pfizer Medical Foundation (ended December 2023). These financial relationships have been mitigated. Dr. Emily Ray has no relevant financial relationships with ineligible companies as defined by the ACCME. CPD staff have no relevant financial relationships with ineligible companies as defined by the ACCME.

**ACCME:** The presenter received consulting fees from Bristol Myers Squibb, G1 Therapeutics, Johnson & Johnson/Janssen Pharmaceuticals, and Pfizer; and research support from Eli Lilly. These financial relationships have been mitigated through slide review by UNC CPD.

**ANCC:** Except as defined above, no one with the ability to control content of this activity has a relevant financial relationship with an ineligible company.

### ACCREDITATION

**NCPD/CNE:** UNC Health is approved as a provider of nursing continuing professional development by the North Carolina Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. Criteria for successful completion to claim CE Certificate requires attendance at the NCPD activity, and submission of an evaluation within 7 days.

**ACPE:** The UNC Eshelman School of Pharmacy Postgraduate/Continuing Education (PGCE) Program provides accredited professional educational activities for pharmacists and pharmacy technicians. The Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill designates this live activity for a maximum of 1.0 ACPE Credit(s).

**ASRT:** The American Registry of Radiologic Technologists (ARRT) is a leading credentialing organization that recognizes qualified individuals in medical imaging, interventional procedures, and radiation therapy. This activity is worth 1 credit hour and is pending approval by the ASRT.

**CME:** The School of Medicine of the University of North Carolina at Chapel Hill is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The School of Medicine of the University of North Carolina at Chapel Hill designates this live internet activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.